Smiths Group PLC Appointment of Smiths Medical CEO (4445B)
June 07 2019 - 2:00AM
UK Regulatory
TIDMSMIN
RNS Number : 4445B
Smiths Group PLC
07 June 2019
News Release
London, 7 June 2019
For immediate release
Appointment of Smiths Medical CEO
Smiths Group plc is pleased to announce the appointment of
JehanZeb Noor as Chief Executive Officer of Smiths Medical.
JehanZeb will be part of Smiths Group's Executive Committee and
report to Andy Reynolds Smith, CEO of Smiths Group plc.
JehanZeb will take up the role on 1 July 2019 and will oversee
the separation of Smiths Medical, which is expected to be completed
during the first half of CY2020.
JehanZeb joins from Amcor Flexibles Inc. ('Amcor'), where he led
the Healthcare North America business and Global Sales for Medical.
Amcor is a specialist producer of sterile packaging for the global
medical device and pharmaceuticals industries. During his
three-year tenure at Amcor he drove a significant improvement in
margin and revenue growth and led the integration of a major
acquisition. Prior to joining Amcor, JehanZeb was a Partner at
McKinsey & Company where he served for 9 years. He has a deep
understanding of the MedTech supply chain, operations,
distribution, product development and regulatory approval
processes. JehanZeb holds a BSc in Finance and a BSc and MSc in
Mechanical Engineering from the Massachusetts Institute of
Technology.
Andy Reynolds Smith, Chief Executive of Smiths Group,
commented:
"I look forward to working with JehanZeb as we continue building
a strong, sustainable future for Smiths Medical and progress the
separation of the business from Smiths Group. I am confident that
JehanZeb's intimate understanding of the MedTech industry combined
with his strong track record of effective leadership, delivering
growth and enhanced performance will make him a great success."
JehanZeb Noor, Smiths Medical Chief Executive Officer Designate,
commented:
"Smiths Medical is an industry leader, offering high quality
specialised medical devices across the globe with significant
investment in new products. The company will begin an exciting new
chapter when it separates from the wider Group and I'm looking
forward to the opportunity to join the team and lead the journey
ahead to achieve our full potential, while serving a life saving
mission."
END
Enquiries:
Investor enquiries
Jemma Spalton, Smiths Group Marion Le Bot, Smiths Group
+44 (0)20 7004 1637 +44 (0)20 7004 1672
+44 (0)78 6739 0350 +44 (0)75 8315 4386
jemma.spalton@smiths.com marion.lebot@smiths.com
Media enquiries
Deborah Scott, FTI Consulting Alex Le May, FTI Consulting
+44 (0)20 3727 1459 +44 (0)20 3727 1308
+44 (0)797 953 7449 +44 (0)7702 443 312
smiths@fticonsulting.com smiths@fticonsulting.com
Legal Entity Identifier (LEI): 213800MJL6IPZS3ASA11
About Smiths Group
Smiths is a global technology company listed on the London Stock
Exchange (SMIN) and operates a sponsored level one ADR programme
(SMGZY). Its businesses share common characteristics
(well-positioned in growing markets, technology-led, asset-light,
digitising, with a high proportion of aftermarket revenues) and a
common operating model (The Smiths Excellence System). For more
information visit www.smiths.com.
About Smiths Medical
Smiths Medical is a leading supplier of specialised medical
devices and equipment for global markets, focusing on medication
delivery, vital care and safety devices. For more information visit
www.smiths-medical.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFFMATMBAMBLL
(END) Dow Jones Newswires
June 07, 2019 02:00 ET (06:00 GMT)
Smiths (LSE:SMIN)
Historical Stock Chart
From Apr 2024 to May 2024
Smiths (LSE:SMIN)
Historical Stock Chart
From May 2023 to May 2024